Home page

全部分类



Cardiovascular And Cerebrovascular Department

Entacapone Tablets

Adjuvant therapy to levodopa/benserazide or levodopa/carbidopa for the treatment of Parkinson's disease and wearing-off phenomenon (symptom fluctuation) not adequately controlled by these standards of care

Product Category：

Product Description

[Product Name] Entacapone Tablets

[Generic Name] Entacapone Tablets

[Approval No.] GYZZ H20213207

[Specification] YBH02492021

[Dosage and Administration] This is an oral formulation that should be used in combination with levodopa/benserazide or levodopa/carbidopa. The prescribing information of these levodopa preparations also applies when they are used in combination with this product. This product can be taken with or without food. When used in combination with levodopa/dopa decarboxylase inhibitor, 0.2 g (one tablet) of this product should be given per dose. The maximum recommended dose is 0.2 g (one tablet) 10 times daily, equivalent to 2 g.

[Indications] Adjuvant therapy to levodopa/benserazide or levodopa/carbidopa for the treatment of Parkinson's disease and wearing-off phenomenon (symptom fluctuation) not adequately controlled by these standards of care

[Strength] 0.2g

[Storage] Store in airtight containers

[Packaging] 0.2 g*30 tablets/carton

[Manufacturer] Sunshine Lake Pharma Co., Ltd.

[China General Distributor] Shenzhen Foncoo Pharmaceutical Co., Ltd.

ONLINE MESSAGE

*Note: Please be sure to fill in the information accurately and keep the communication open, we will get in touch with you as soon as possible